Federal Hemp Loophole & Intoxicating Hemp Products: Legal Status Guide

Executive Summary

The 2018 Farm Bill's definition of hemp as cannabis containing less than 0.3% delta-9 THC by dry weight created an unintended regulatory gap that has spawned a multi-billion-dollar market for intoxicating hemp-derived products sold outside state-licensed cannabis systems. This loophole allows manufacturers to extract, synthesize, and concentrate cannabinoids including delta-8 THC, delta-10 THC, THC-O, HHC, and others from legal hemp, then sell them in gas stations, convenience stores, and now major retailers like Target without the testing, taxation, or age verification requirements imposed on state-regulated marijuana programs. As of May 2026, Target's expansion into hemp-derived THC beverages across Florida, Texas, and Illinois marks the most significant mainstream retail adoption of these products to date, underscoring both the commercial viability and regulatory confusion surrounding the federal hemp framework.

The controversy centers on whether Congress intended to legalize intoxicating products when it removed hemp from the Controlled Substances Act. The Drug Enforcement Administration, Food and Drug Administration, and state regulators have issued conflicting guidance, while industry stakeholders argue the products meet the statutory definition of legal hemp. An estimated $2.8 billion in intoxicating hemp products were sold in the United States in 2025, according to market research firm Whitney Economics, with projections reaching $4.1 billion by 2027. The regulatory vacuum has created a parallel cannabis market that operates without the seed-to-sale tracking, potency limits, pesticide testing, or excise taxes that govern state-licensed marijuana businesses, raising concerns among public health officials, state regulators, and licensed cannabis operators who face significantly higher compliance costs.

The debate has intensified as products have proliferated beyond specialty shops into mainstream retail channels. Target's decision to stock hemp-derived THC beverages in more than 300 stores across three states represents a watershed moment, signaling that major corporations view the legal risk as manageable and consumer demand as substantial enough to justify shelf space. The move comes as approximately 18 states have enacted restrictions or outright bans on intoxicating hemp products, while others have established regulatory frameworks attempting to bring them into existing cannabis control systems. Federal legislation to close the loophole has been introduced repeatedly but has not advanced, leaving the market in a state of legal ambiguity that shows no signs of resolution.

Why This Matters

The federal hemp loophole affects cannabis operators, hemp farmers, consumers, public health officials, state tax authorities, and federal regulators across a market that generated $2.8 billion in sales in 2025 and is projected to reach $4.1 billion by 2027.

For state-licensed cannabis operators, intoxicating hemp products represent direct competition from an unregulated market. Dispensaries in states like Colorado, California, and Michigan report losing customers to hemp shops and gas stations selling similar products at lower prices without the 15-37% excise taxes imposed on licensed marijuana. The National Cannabis Industry Association has called the situation "the greatest threat to the regulated cannabis industry," noting that licensed operators invest millions in compliance infrastructure while hemp competitors face minimal barriers to entry. In Illinois, where recreational cannabis carries a 25% excise tax plus local taxes reaching 3%, hemp-derived THC beverages at Target will compete directly with dispensary products at significantly lower price points.

State governments face substantial revenue implications. Colorado collected $423 million in marijuana tax revenue in 2025, according to the state Department of Revenue, but officials estimate the state lost $60-80 million in potential revenue to untaxed hemp products. California's cannabis excise tax revenue declined 8.3% year-over-year in fiscal 2025, a drop the state Legislative Analyst's Office partially attributed to hemp product competition. States that have built budgets around cannabis tax projections now confront a structural revenue challenge as consumers shift to cheaper, untaxed alternatives.

Public health stakeholders express concern about the absence of testing requirements, potency limits, and age verification enforcement. Unlike state-licensed cannabis products, which undergo mandatory testing for pesticides, heavy metals, microbials, and potency, hemp-derived products face no federal testing mandates. A 2025 study by the U.S. Cannabis Council found that 38% of hemp-derived delta-8 THC products tested contained illegal delta-9 THC levels exceeding 0.3%, while 22% contained contaminants including heavy metals or pesticide residues. The American Academy of Pediatrics has called for federal action, citing emergency department visits involving minors who consumed mislabeled or high-potency hemp products.

For hemp farmers and processors, the loophole has created a lucrative market for biomass that would otherwise have minimal value. Hemp flower suitable for cannabinoid extraction sold for an average of $385 per pound in 2025, according to Hemp Benchmarks, compared to $2-4 per pound for fiber hemp. The market has sustained thousands of farms that entered hemp production after the 2018 Farm Bill, particularly in Kentucky, North Carolina, Tennessee, and Oregon. Industry groups including the U.S. Hemp Roundtable argue that restricting intoxicating products would devastate the agricultural sector and eliminate the primary revenue stream for most hemp farmers.

Background and History

The federal hemp loophole emerged from the Agricultural Improvement Act of 2018, commonly known as the 2018 Farm Bill, which removed hemp from Schedule I of the Controlled Substances Act and defined it as cannabis containing not more than 0.3% delta-9 tetrahydrocannabinol on a dry weight basis.

The 2018 Farm Bill and Hemp Legalization

President Donald Trump signed the Agriculture Improvement Act of 2018 into law on December 20, 2018. Section 10113 of the legislation amended the Agricultural Marketing Act of 1946 to define hemp as "the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis." The statute explicitly removed hemp from the definition of marijuana in the Controlled Substances Act, 21 U.S.C. § 802(16).

The 0.3% threshold was not based on pharmacological research but rather on a 1976 taxonomic paper by Canadian plant scientists Ernest Small and Arthur Cronquist, who proposed the arbitrary cutoff to distinguish fiber and seed cultivars from drug cultivars. Congress adopted this botanical distinction as a legal standard without extensive consideration of how extraction and concentration processes could transform compliant hemp into intoxicating products. Senate Majority Leader Mitch McConnell, the bill's primary champion, stated the legislation was intended to support Kentucky hemp farmers producing fiber, grain, and CBD products, according to floor statements in the Congressional Record. There is no evidence in the legislative history that Congress contemplated or intended to legalize intoxicating cannabinoid products.

The Emergence of Delta-8 THC Products

Delta-8 tetrahydrocannabinol, a minor cannabinoid that occurs naturally in cannabis at concentrations typically below 1%, became the first major intoxicating product to exploit the hemp loophole. In 2019 and 2020, chemists discovered they could efficiently convert CBD, which is abundant in hemp, into delta-8 THC through a process involving dissolution in organic solvents and exposure to acids. The resulting delta-8 THC produces psychoactive effects similar to but reportedly milder than delta-9 THC, the primary intoxicating compound in marijuana.

Delta-8 THC products appeared in smoke shops and online retailers in late 2019, but the market exploded in 2020 and 2021 as the COVID-19 pandemic drove consumers to seek legal alternatives to state-regulated cannabis. The products were marketed as "legal THC" and "federally compliant," claims based on the argument that delta-8 THC derived from hemp meets the statutory definition because the final product contains less than 0.3% delta-9 THC, even though it may contain 90%+ delta-8 THC. By mid-2021, delta-8 products were available in an estimated 40,000 retail locations nationwide, including gas stations, convenience stores, and vape shops.

DEA and FDA Responses

The Drug Enforcement Administration issued an Interim Final Rule on August 21, 2020, implementing the 2018 Farm Bill's hemp provisions. The rule stated that "all synthetically derived tetrahydrocannabinols remain schedule I controlled substances," citing 21 CFR § 1308.11(d)(31). The DEA clarified in a May 2021 letter to the Alabama Board of Pharmacy that delta-8 THC produced through chemical synthesis from CBD is a controlled substance because it does not occur naturally in the plant extract in significant amounts.

However, the DEA has not initiated enforcement actions against delta-8 manufacturers or retailers, creating a de facto tolerance policy. Industry attorneys argue that isomerization of CBD to delta-8 THC is a conversion rather than a synthesis, and that the resulting compound is a "derivative" of hemp explicitly permitted under the statutory language. The legal ambiguity has persisted for more than five years without federal court resolution, as the DEA has not brought cases that would force judicial interpretation of the statute.

The Food and Drug Administration has taken a different approach, focusing on marketing claims and product safety rather than controlled substance status. The FDA issued warning letters to several delta-8 manufacturers in 2021 and 2022 for making unapproved drug claims and marketing products with inadequate safety data. In a May 2022 statement, the FDA noted it had received 104 adverse event reports involving delta-8 THC products between December 2020 and February 2022, including hospitalizations and emergency department visits. However, the agency has not established a comprehensive regulatory framework for hemp-derived cannabinoids, leaving the market largely unregulated at the federal level.

Proliferation of Novel Cannabinoids

The commercial success of delta-8 THC spawned a wave of additional hemp-derived intoxicating products. Manufacturers introduced delta-10 THC, THC-O acetate, HHC (hexahydrocannabinol), THC-P (tetrahydrocannabiphorol), and other cannabinoids produced through chemical processes starting with hemp-derived CBD. By 2023, the market included more than 15 distinct intoxicating cannabinoids sold as "legal hemp products," according to a survey by the Hemp Industries Association.

In February 2023, the DEA issued a letter clarifying that THC-O acetate is not a naturally occurring cannabinoid and does not fall under the hemp exemption, effectively declaring it a Schedule I controlled substance. The agency noted that THC-O is produced through acetylation of THC and "does not occur naturally in the cannabis plant," making it a controlled substance analog under 21 U.S.C. § 813. This marked the DEA's first explicit enforcement position on a specific hemp-derived cannabinoid beyond delta-8, though actual prosecutions have remained rare.

State Legislative Responses

States began responding to intoxicating hemp products in 2021, with approaches ranging from outright bans to regulatory frameworks. Alaska became the first state to explicitly ban delta-8 THC in March 2021, amending its controlled substances statute to include all tetrahydrocannabinols regardless of source. Colorado, which has a mature regulated cannabis market, banned delta-8 and similar products in June 2021, with the Department of Revenue stating that intoxicating products must be sold through licensed dispensaries.

By May 2026, approximately 18 states have enacted restrictions or bans on intoxicating hemp products, while others have established regulatory frameworks. Oregon's House Bill 3000, effective January 2024, brought hemp-derived intoxicating products under the Oregon Liquor and Cannabis Commission's jurisdiction, requiring testing, labeling, and retail licensing. Minnesota's 2023 legislation created a regulatory framework for "hemp-derived consumer products" containing up to 5 milligrams of THC per serving and 50 milligrams per package, with products sold through licensed retailers subject to testing and age verification.

Target's Entry and Mainstream Retail Adoption

Target's May 2026 announcement that it would stock hemp-derived THC beverages in more than 300 stores across Florida, Texas, and Illinois represents the most significant mainstream retail adoption to date. The company is carrying products from Cann, a cannabis beverage brand that launched a hemp-derived line in 2025, and other manufacturers producing beverages with 5-10 milligrams of hemp-derived THC per can. Target's decision follows similar moves by regional grocery chains including Kroger subsidiaries in select markets and convenience store chains like Circle K, which began testing hemp beverage sales in 2025.

The retail expansion reflects growing consumer acceptance and manufacturer sophistication. Hemp-derived THC beverages have evolved from early products with inconsistent potency and poor taste profiles to offerings that rival state-licensed cannabis beverages in quality and branding. Manufacturers have invested in emulsion technology, flavor development, and packaging that appeals to mainstream consumers rather than traditional cannabis users. The products are marketed as "sessionable" alternatives to alcohol, with serving sizes designed to produce mild effects comparable to one or two alcoholic drinks.

Key Players

Target Corporation

Target Corporation's decision to stock hemp-derived THC beverages in Florida, Texas, and Illinois stores marks the first major national retailer to embrace intoxicating hemp products at scale. The Minneapolis-based retailer operates approximately 1,950 stores nationwide and generated $107 billion in revenue in fiscal 2025. Target's entry into the category signals that major corporations view the legal risk as manageable and consumer demand as sufficient to justify shelf space in the beverage alcohol section.

According to BevNet, Target will carry the products in all Florida and Texas locations, plus select Illinois stores in municipalities that permit intoxicating hemp sales. The company has not disclosed sales projections or expansion plans to additional states. A Target spokesperson stated the company "continuously evaluates new products that meet legal requirements and customer preferences," but declined to comment on the regulatory analysis underlying the decision.

Cann

Cann, a Los Angeles-based cannabis beverage company founded in 2019, launched a hemp-derived product line in 2025 to access markets outside state-licensed cannabis systems. The company's hemp beverages contain 5 milligrams of hemp-derived delta-9 THC per 12-ounce can, positioning them as "microdose" products comparable to the company's state-licensed offerings. Cann co-founder and CEO Luke Anderson stated in a 2025 interview with MG Magazine that the hemp line allows the company to reach consumers in states without adult-use cannabis programs and to access mainstream retail channels closed to marijuana products.

Cann raised $27 million in Series A funding in 2021, with investors including Imaginary Ventures and Baron Davis Enterprises. The company reported it sold more than 10 million cans across state-licensed and hemp-derived products in 2025, making it one of the largest cannabis beverage brands by volume. The hemp line's placement in Target stores represents a significant distribution expansion beyond the company's existing channels of dispensaries, specialty retailers, and direct-to-consumer sales.

Drug Enforcement Administration

The Drug Enforcement Administration's ambiguous position on hemp-derived intoxicating products has created the regulatory vacuum enabling the market. While the agency's August 2020 Interim Final Rule stated that synthetically derived tetrahydrocannabinols remain Schedule I controlled substances, and subsequent letters clarified that delta-8 THC produced through chemical conversion is controlled, the DEA has not initiated enforcement actions against manufacturers or retailers. DEA Administrator Anne Milgram stated in Congressional testimony in March 2025 that the agency views hemp-derived intoxicating products as "a matter requiring legislative clarification rather than enforcement action," according to testimony before the House Judiciary Committee.

The agency's position reflects both resource constraints and legal uncertainty. DEA officials have privately acknowledged that prosecuting hemp-derived cannabinoid cases would require proving that specific products were produced through prohibited synthetic processes rather than permitted extraction and derivation from hemp, a distinction that may be difficult to establish in court. The lack of enforcement has emboldened manufacturers and retailers, who interpret the DEA's inaction as tacit acceptance of the market.

Food and Drug Administration

The Food and Drug Administration has focused on product safety and marketing claims rather than controlled substance status. The agency has issued warning letters to manufacturers for making unapproved drug claims, selling products with inadequate safety data, and marketing to minors. In January 2023, the FDA announced it was evaluating a regulatory pathway for CBD products but has not extended that process to intoxicating hemp-derived cannabinoids.

FDA Principal Deputy Commissioner Janet Woodcock testified before the Senate Committee on Health, Education, Labor and Pensions in June 2024 that the agency lacks sufficient data to establish safe levels of THC consumption from hemp products and called for Congressional action to clarify the agency's authority. The FDA's position is that all THC-containing products are subject to the Federal Food, Drug, and Cosmetic Act's drug approval requirements if marketed with therapeutic claims, but the agency has not attempted to regulate hemp-derived THC products as unapproved drugs when marketed for recreational purposes.

U.S. Hemp Roundtable

The U.S. Hemp Roundtable, a coalition of hemp farmers, processors, and manufacturers, has advocated for preserving access to hemp-derived cannabinoid products while supporting "reasonable regulations" including age restrictions, testing requirements, and labeling standards. The organization argues that the 2018 Farm Bill's language explicitly permits "all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers" of hemp, and that Congress knew or should have known this language would encompass intoxicating compounds.

Jonathan Miller, general counsel for the U.S. Hemp Roundtable, stated in a 2024 white paper that "the solution is not to ban hemp-derived cannabinoids but to regulate them appropriately, with testing, labeling, and retail restrictions comparable to alcohol." The organization has supported state legislation establishing regulatory frameworks rather than outright bans, arguing that prohibition would drive the market underground and eliminate the economic benefits to hemp farmers.

National Cannabis Industry Association

The National Cannabis Industry Association, representing state-licensed cannabis operators, has called for federal action to close the hemp loophole and require intoxicating products to be sold through regulated channels. The organization argues that the current situation creates an unfair competitive advantage for hemp products, which avoid the testing, taxation, and compliance costs imposed on licensed marijuana businesses. NCIA CEO Aaron Smith stated in a February 2026 press release that "allowing intoxicating products to be sold in gas stations without testing or age verification undermines state regulatory systems and puts consumers at risk."

The association has supported federal legislation including the Hemp and Hemp-Derived Consumer Products Market Act, introduced in 2024, which would require intoxicating hemp products to be sold through state-licensed channels with testing and taxation comparable to marijuana. The bill has not advanced beyond committee referral, reflecting the political complexity of cannabis policy and disagreement among industry stakeholders about the appropriate regulatory approach.

Legal and Regulatory Framework

The legal status of intoxicating hemp products rests on competing interpretations of the Agricultural Improvement Act of 2018, the Controlled Substances Act, and the Federal Food, Drug, and Cosmetic Act, with no definitive federal court rulings resolving the ambiguity.

Statutory Language and Interpretation

The 2018 Farm Bill defines hemp at 7 U.S.C. § 1639o as "the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis." The statute removes hemp from the definition of marijuana in 21 U.S.C. § 802(16), effectively exempting it from Schedule I control under the Controlled Substances Act.

Proponents of intoxicating hemp products argue that the phrase "all derivatives, extracts, cannabinoids, isomers" encompasses delta-8 THC and other cannabinoids produced from hemp, provided the final product contains less than 0.3% delta-9 THC. This interpretation relies on the principle that Congress included expansive language that must be given effect, and that limiting "cannabinoids" to non-intoxicating compounds would render the statutory language meaningless since the 0.3% delta-9 threshold already serves that function.

Opponents argue that the statute's focus on delta-9 THC concentration reflects Congressional intent to legalize non-intoxicating hemp products, and that interpreting the law to permit intoxicating cannabinoids produced through chemical processes defeats that purpose. They note that the DEA's Interim Final Rule at 21 CFR § 1308.11(d)(31) classifies "synthetically derived tetrahydrocannabinols" as Schedule I controlled substances, and that cannabinoids produced through isomerization or other chemical conversions are synthetic under established DEA interpretations.

The Synthetic Cannabinoid Question

The central legal dispute concerns whether hemp-derived cannabinoids produced through chemical conversion processes are "synthetic" and therefore remain controlled substances, or are "derivatives" of hemp and therefore legal. The DEA's position, articulated in the August 2020 Interim Final Rule and subsequent guidance letters, is that tetrahydrocannabinols that do not occur naturally in the plant in significant concentrations and are produced through chemical synthesis remain Schedule I controlled substances under 21 U.S.C. § 812.

The DEA has defined synthetic cannabinoids broadly to include compounds produced through chemical modification of naturally occurring cannabinoids. In a May 2021 letter to the Alabama Board of Pharmacy, the DEA stated that delta-8 THC "does not occur in nature in more than trace amounts" and that delta-8 products are "synthetically produced in a laboratory from CBD extracted from hemp." The agency concluded that such products are controlled substances.

Industry attorneys counter that the term "synthetic" should be interpreted narrowly to mean compounds with no natural analog in cannabis, such as the synthetic cannabinoid receptor agonists (e.g., "Spice" or "K2") that the DEA has scheduled. They argue that delta-8 THC, which does occur naturally in cannabis even if in small amounts, and which is produced by converting one natural cannabinoid (CBD) into another (delta-8 THC) through isomerization, is a "derivative" rather than a synthetic compound. This interpretation has not been tested in federal court, as the DEA has not brought enforcement actions that would force judicial resolution.

FDA Authority and Food Safety

The Federal Food, Drug, and Cosmetic Act at 21 U.S.C. § 301 et seq. grants the FDA authority over food, drugs, and dietary supplements. The FDA's position is that THC-containing products marketed with therapeutic claims are unapproved drugs subject to the agency's drug approval requirements. However, the FDA has not attempted to regulate hemp-derived THC products marketed for recreational purposes as unapproved drugs, focusing instead on safety concerns and marketing practices.

The FDA's authority to regulate hemp-derived cannabinoids as food additives or dietary supplement ingredients is complicated by the drug exclusion rule at 21 U.S.C. § 321(ff)(3)(B), which prohibits substances that have been approved as drugs or subjected to substantial clinical investigation from being marketed as dietary supplements. Because THC is the active ingredient in FDA-approved drugs including Marinol (dronabinol) and Epidiolex (cannabidiol), the agency could argue that THC-containing products are excluded from the dietary supplement pathway. However, the FDA has not pursued this theory in enforcement actions.

State-Level Regulatory Approaches

States have adopted four general approaches to intoxicating hemp products: outright bans, integration into existing cannabis regulatory systems, standalone hemp cannabinoid frameworks, and inaction. As of May 2026, approximately 18 states have enacted bans or significant restrictions, while others have created regulatory pathways.

Ban states include Alaska, Colorado, Delaware, Idaho, Iowa, Montana, New York, North Dakota, Rhode Island, Utah, Vermont, and Washington. These states have amended controlled substances statutes to include all tetrahydrocannabinols regardless of source, or have explicitly prohibited hemp-derived intoxicating products through separate legislation. Enforcement varies, with some states actively prosecuting retailers while others rely on cease-and-desist orders.

Integration states including Oregon and Connecticut have brought hemp-derived intoxicating products under existing cannabis regulatory agencies, requiring testing, labeling, and sale through licensed retailers. Oregon's approach, implemented through House Bill 3000 in 2024, treats hemp-derived THC products as equivalent to marijuana products for regulatory purposes, with the same testing requirements, potency limits, and retail restrictions.

Standalone framework states including Minnesota, Louisiana, and Arkansas have created separate regulatory systems for hemp-derived products with lower potency limits and less stringent requirements than marijuana programs. Minnesota's framework allows products with up to 5 milligrams of THC per serving and 50 milligrams per package, sold through licensed retailers subject to age verification and basic testing requirements but without the seed-to-sale tracking required for marijuana.

State-by-State Breakdown

State approaches to intoxicating hemp products vary dramatically, creating a patchwork regulatory landscape that complicates interstate commerce and consumer understanding.

Florida

Florida has not enacted restrictions on hemp-derived intoxicating products, making it one of the largest open markets. The state's hemp program, administered by the Department of Agriculture and Consumer Services under Florida Statutes § 581.217, implements the 2018 Farm Bill without additional restrictions on cannabinoid content beyond the 0.3% delta-9 THC limit. Florida does not have an adult-use marijuana program, making hemp-derived products the only legal intoxicating cannabis option for recreational consumers.

The Florida Legislature considered bills in 2023 and 2024 to restrict intoxicating hemp products but did not advance them to passage. Industry sources estimate Florida's hemp-derived cannabinoid market generated $400-500 million in sales in 2025. Target's decision to stock hemp beverages in all Florida locations reflects the state's permissive regulatory environment and substantial consumer demand. The state requires hemp retailers to verify purchaser age at 21 or older under Florida Statutes § 581.217(3)(b), but does not mandate product testing, potency limits, or retail licensing beyond general business requirements.

Texas

Texas legalized hemp under House Bill 1325 in 2019, implementing the 2018 Farm Bill through Texas Health and Safety Code § 443. The state has not enacted additional restrictions on hemp-derived intoxicating products, though the Texas Department of State Health Services issued guidance in 2021 stating that delta-8 THC is a Schedule I controlled substance. However, the agency has not enforced this position, and hemp-derived products remain widely available throughout the state.

Texas does not have an adult-use marijuana program, and medical cannabis is limited to low-THC products for specific conditions under the Texas Compassionate Use Act. This creates substantial demand for hemp-derived alternatives. Industry estimates suggest Texas's hemp-derived cannabinoid market reached $350-450 million in sales in 2025, making it one of the three largest state markets alongside Florida and California. Target's decision to stock products in all Texas locations reflects both the legal ambiguity and the market size. Age verification at 21 is required under state law, but testing and potency limits are not mandated.

Illinois

Illinois has taken a more restrictive approach than Florida or Texas, though it has not banned hemp-derived intoxicating products outright. The Illinois Department of Agriculture regulates hemp under the Hemp Act, 505 ILCS 89, which implements federal requirements without additional cannabinoid restrictions at the state level. However, municipalities have authority to prohibit hemp-derived intoxicating products, and approximately 40% of Illinois jurisdictions have enacted local bans or restrictions as of May 2026.

Illinois has a mature adult-use marijuana program established under the Cannabis Regulation and Tax Act, 410 ILCS 705, with recreational sales beginning January 1, 2020. The state collected $445 million in cannabis tax revenue in fiscal 2025, according to the Illinois Department of Financial and Professional Regulation. Licensed cannabis operators have lobbied for restrictions on hemp-derived products, arguing they undermine the regulated market. Target's decision to stock hemp beverages only in municipalities that permit them reflects the fragmented local regulatory landscape. Products are subject to age verification at 21 but not state-mandated testing or potency limits.

California

California has not enacted a statewide ban on hemp-derived intoxicating products but has brought them under the Department of Cannabis Control's jurisdiction through Assembly Bill 45, effective January 2024. The law requires hemp products containing detectable amounts of THC to comply with the same testing, labeling, and manufacturing requirements as marijuana products, though they can be sold outside licensed dispensaries. Products must contain less than 0.3% delta-9 THC and less than 0.5 milligrams of THC per serving, with a maximum of 2 milligrams per package for ingestible products.

The restrictions effectively limit hemp-derived products to very low potencies, making them less commercially viable than in states with no potency caps. California's approach reflects an attempt to preserve the regulated cannabis market while allowing low-dose hemp products. The state's cannabis excise tax revenue declined 8.3% in fiscal 2025, a drop the Legislative Analyst's Office attributed partly to hemp product competition before AB 45's implementation. Target has not announced plans to stock hemp beverages in California, likely due to the restrictive potency limits.

Colorado

Colorado banned delta-8 THC and similar hemp-derived intoxicating products in June 2021, with the Department of Revenue's Marijuana Enforcement Division issuing guidance that products containing any amount of THC, regardless of source, must be sold through licensed dispensaries. The state amended its controlled substances statute to include all tetrahydrocannabinols, closing the hemp loophole. Colorado's position is that the 2018 Farm Bill did not preempt state authority to regulate intoxicating substances, and that protecting the state's regulated cannabis market requires prohibiting unregulated alternatives.

Enforcement has been active, with the Marijuana Enforcement Division conducting compliance checks and issuing cease-and-desist orders to retailers selling hemp-derived intoxicating products. The state's approach reflects concern that unregulated products undermine the testing, taxation, and public health protections built into Colorado's cannabis framework. Colorado collected $423 million in marijuana tax revenue in 2025, and officials have stated that preserving that revenue stream requires preventing untaxed competition.

Oregon

Oregon's House Bill 3000, effective January 2024, brought hemp-derived intoxicating products under the Oregon Liquor and Cannabis Commission's jurisdiction. Products containing more than 0.5 milligrams of THC per serving must be sold through OLCC-licensed retailers and comply with the same testing, labeling, and packaging requirements as marijuana products. The law established a tiered system with lower-potency products (0.5-5 milligrams per serving) subject to less stringent requirements than higher-potency products, which must meet full marijuana regulatory standards.

Oregon's approach attempts to balance hemp industry interests with regulatory control, allowing products to remain legal while subjecting them to oversight. The OLCC issued final rules in December 2023 establishing testing requirements for pesticides, heavy metals, solvents, and potency, along with child-resistant packaging and serving size limits. Products must be manufactured in licensed facilities and sold through retailers with age verification systems. The framework has reduced the number of hemp retailers while bringing remaining operators into compliance with safety standards.

Market and Business Implications

The intoxicating hemp market reached $2.8 billion in sales in 2025 and is projected to grow to $4.1 billion by 2027, creating significant implications for multi-state cannabis operators, hemp farmers, beverage companies, and mainstream retailers.

Impact on Licensed Cannabis Operators

Update — May 19, 2026: Former Coast Guard Officer Faces Federal Crackdown on Texas Hemp Operation

Lukas Gilkey, who previously served boarding drug interdiction vessels in the Caribbean Sea for the U.S. Coast Guard, now operates one of Texas' largest hemp companies—and faces potential federal enforcement action targeting his intoxicating hemp products. Gilkey's career shift from federal drug enforcement to hemp manufacturing underscores the regulatory paradox facing operators who built businesses under the 2018 Farm Bill's hemp legalization framework, according to High Times.

The looming federal action against Gilkey's company reflects intensified DEA and FDA scrutiny of delta-8 THC and other hemp-derived intoxicants that proliferated after 2018. Gilkey's experience interdicting narcotics shipments reportedly shaped his view that drug prohibition policies were ineffective, motivating his transition into legal hemp commerce. His company capitalized on the 0.3% delta-9 THC threshold in the Farm Bill to manufacture products containing alternative cannabinoids not explicitly scheduled under the Controlled Substances Act.

Texas hemp operators face particular vulnerability as state legislators consider bills restricting intoxicating hemp products while federal agencies signal enforcement priorities targeting products marketed for psychoactive effects. Gilkey's case illustrates the precarious legal position of hemp businesses that interpreted the Farm Bill as authorizing intoxicating cannabinoid products, a reading contested by federal regulators. The irony of a former drug enforcement officer now targeted by federal cannabis policy enforcement highlights the unresolved statutory ambiguities in hemp regulation that have enabled a multi-billion dollar intoxicating hemp market.

For hemp operators and investors, Gilkey's situation demonstrates enforcement risk even for large-scale state-compliant operations. The federal government's shifting posture toward intoxicating hemp—from tacit tolerance to active enforcement consideration—creates material uncertainty for companies holding inventory, retail contracts, or financing arrangements predicated on continued legal market access for delta-8 THC and similar compounds derived from compliant hemp biomass.

Update — May 19, 2026: Colorado regulator acknowledges massive illegal hemp market in leaked recording

A top official with Colorado's Marijuana Enforcement Division said in a leaked meeting recording that the size of the state's illegal hemp market "would explode your minds," according to reporting by the Denver Gazette via ProPublica. The official acknowledged that Colorado, as the first state to legalize cannabis, has faced "unintended consequences and unforeseen outcomes" in managing the parallel hemp and marijuana regulatory frameworks.

The remarks underscore ongoing enforcement challenges in Colorado, where intoxicating hemp products sold outside the licensed marijuana system have proliferated since the 2018 Farm Bill federally legalized hemp. State regulators have struggled to distinguish compliant hemp from illegal marijuana-derived products, particularly as delta-8 THC and other hemp-derived cannabinoids entered retail channels without the testing, taxation, or age restrictions applied to licensed dispensaries.

Colorado's experience highlights the regulatory arbitrage created when federal hemp law conflicts with state marijuana licensing regimes. Licensed operators face higher compliance costs, while unlicensed hemp retailers can sell similar intoxicating products with minimal oversight. The leaked recording suggests state enforcement resources remain insufficient to close the gap, despite legislative efforts to tighten hemp rules in recent sessions.

For operators, the admission signals that enforcement priorities may shift as regulators confront the scale of the illicit hemp market. Investors in licensed cannabis businesses should note that competitive pressure from unregulated hemp products continues to erode market share in early-legal states, with Colorado serving as a cautionary case study for other jurisdictions navigating the federal hemp loophole.

Update — May 21, 2026: North Carolina retailer highlights regulatory gaps in intoxicating hemp market

GreenLife Remedies owner discussed the operational challenges of selling Delta-8 THC and other hemp-derived intoxicating cannabinoids in North Carolina, according to the Charlotte Observer. The retailer emphasized that lack of federal and state testing standards creates consumer safety concerns, as products remain legal under the 2018 Farm Bill but face no mandatory potency verification or contaminant screening requirements.

North Carolina operates without a comprehensive hemp-derived cannabinoid regulatory framework, leaving retailers to self-regulate product sourcing and lab testing protocols. GreenLife Remedies voluntarily requires third-party certificates of analysis for all inventory, though no state statute mandates such verification for hemp retailers. The absence of enforcement mechanisms means non-compliant operators face minimal legal consequences for selling untested or mislabeled products.

The retailer noted that consumer confusion between hemp-derived Delta-8 THC and marijuana-derived Delta-9 THC persists due to overlapping product formats and marketing. Both compounds produce psychoactive effects, but Delta-8 remains federally legal under the 0.3% Delta-9 THC dry-weight threshold established in 7 U.S.C. § 1639o. This distinction matters for interstate commerce, as hemp products can cross state lines while marijuana cannot.

Industry stakeholders continue advocating for federal rulemaking on hemp-derived intoxicants, particularly regarding age restrictions and serving-size limits. The FDA has not issued final guidance on hemp-derived cannabinoids in consumable products, leaving enforcement to state authorities. North Carolina's legislative session includes no pending bills addressing intoxicating hemp regulation as of May 2026.

Update — May 28, 2026: Federal Hemp Loophole Closure Sparks Industry and Regulatory Debate

Federal authorities moved to close the regulatory gap that allowed intoxicating hemp-derived products to proliferate under the 2018 Farm Bill's 0.3% delta-9 THC dry-weight threshold. The Hemp Gazette reported that new federal guidance reinterprets the Farm Bill to exclude synthetically derived cannabinoids and products designed for intoxication, effectively ending the legal pathway for delta-8 THC, THC-O, and similar semi-synthetic compounds sold in gas stations and convenience stores nationwide. The guidance, issued jointly by the U.S. Department of Agriculture and the Drug Enforcement Administration, clarifies that only naturally occurring cannabinoids in hemp below the 0.3% delta-9 THC limit qualify for Farm Bill protections.

Industry stakeholders responded with sharp divisions. The National Hemp Association said the move creates immediate compliance burdens for an estimated 15,000 U.S. hemp processors and retailers who relied on the previous interpretation. According to the trade group, manufacturers face potential inventory seizures and civil penalties unless they reformulate or discontinue products within a 90-day grace period. Conversely, state-licensed cannabis operators welcomed the clarification, arguing that unregulated intoxicating hemp products undercut tax-paying dispensaries and lacked safety testing requirements.

The regulatory shift follows mounting pressure from state attorneys general and public health officials. At least 22 states enacted their own restrictions on intoxicating hemp products between 2022 and 2025, creating a patchwork of conflicting rules that complicated interstate commerce. The new federal guidance establishes a uniform standard but stops short of banning all hemp-derived intoxicants; products meeting the natural-occurrence test and THC threshold remain permissible. Legal experts anticipate industry lawsuits challenging the agencies' statutory authority to redefine "hemp" beyond Congress's 2018 language.

Financial analysts project significant market consolidation. Investment firm Viridian Capital Advisors estimated that the intoxicating hemp sector generated $2.8 billion in U.S. sales during 2025, with delta-8 THC products accounting for approximately 60% of revenue. The guidance threatens to redirect consumer demand toward state-regulated cannabis markets or compliant CBD products, reshaping supply chains and forcing smaller hemp companies to exit or pivot. Compliance costs for lab testing and reformulation are expected to disproportionately impact operators without access to capital or legal counsel.

Update — June 3, 2026: Former Indiana Attorney General Urges Congress to Close Hemp Loophole

Former Indiana Attorney General Curtis Hill published an opinion piece urging Congress to maintain restrictions on intoxicating hemp products and avoid reopening what he described as the federal hemp loophole. Hill argued that the 2018 Farm Act's legalization of hemp with less than 0.3% delta-9 THC created unintended consequences by allowing manufacturers to produce psychoactive cannabinoids such as delta-8 THC, delta-10 THC, and THC-O through chemical conversion processes. According to Hill, these products now compete directly with state-regulated cannabis markets while evading the safety testing, age verification, and taxation requirements imposed on licensed dispensaries.

Hill's commentary comes as Congress considers reauthorization of the Farm Bill, which governs federal hemp policy. At least 22 states have enacted restrictions or outright bans on intoxicating hemp-derived cannabinoids since 2021, according to state legislative tracking data. Hill contended that federal inaction forces states to address public health and regulatory challenges on a piecemeal basis, creating a fragmented legal landscape for consumers and businesses.

The former attorney general emphasized that intoxicating hemp products are widely available in gas stations, convenience stores, and online retailers without age restrictions or product testing in many jurisdictions. He said this accessibility poses risks to minors and undermines state efforts to regulate cannabis through licensed channels. Hill called for Congress to amend the Farm Bill definition of hemp to explicitly exclude all intoxicating cannabinoids, regardless of concentration or source material.

Industry groups representing hemp manufacturers have opposed such restrictions, arguing that hemp-derived cannabinoids provide legal access to therapeutic compounds in states without medical or adult-use cannabis programs. The debate reflects broader tensions between hemp and cannabis industries over market share, regulatory authority, and consumer safety standards. Hill's position aligns with law enforcement organizations and some state regulators who advocate for federal clarification of hemp's legal boundaries.

Update — June 9, 2026: Industry voices call for regulatory repairs as hemp loophole closes

Cannabis Business Times published an opinion piece arguing that closing the federal hemp loophole alone will not address the market disruptions and regulatory gaps created during its years of operation. The commentary noted that intoxicating hemp products flooded retail channels nationwide between 2018 and 2026, creating consumer confusion and undermining state-licensed cannabis programs. The author emphasized that federal and state regulators must now reconcile conflicting product standards, testing protocols, and taxation frameworks left in the wake of unregulated delta-8 THC and similar derivatives.

The piece highlighted persistent challenges in product testing and labeling accuracy, pointing to studies that found significant discrepancies between labeled and actual THC content in hemp-derived products sold at gas stations and convenience stores. According to the opinion, state cannabis operators lost an estimated billions in revenue to untaxed hemp competitors during the loophole's peak years. The author called for Congress to establish clear potency limits, mandatory third-party testing, and age-verification requirements for any remaining hemp-derived cannabinoid products.

The commentary also addressed the need for interstate commerce rules that prevent regulatory arbitrage between states with strict cannabis laws and those with permissive hemp policies. The author argued that without federal coordination, consumers will continue to access intoxicating products through online vendors and cross-border sales, undermining state-level public health protections. The piece concluded by urging the Food and Drug Administration to finalize cannabinoid regulations and provide clear guidance on permissible hemp ingredients in food, beverages, and dietary supplements.

This opinion reflects growing consensus among licensed cannabis operators that closing the loophole requires comprehensive regulatory follow-through rather than simple prohibition. The call for systemic fixes signals that industry stakeholders expect federal agencies to address testing standards, tax equity, and consumer protection gaps that emerged during the eight-year period when intoxicating hemp products operated in a legal gray zone.

Update — June 11, 2026: Industry Analysis Warns Hemp THC Testing Limits Drive CBD Production Offshore

A legal analysis published in The National Law Review argued that federal hemp THC testing protocols intended to ensure safety are instead forcing domestic CBD manufacturers to relocate production overseas, according to attorneys at Foley & Lardner LLP. The article contended that the USDA's pre-harvest THC testing window—requiring samples within 15 days of harvest—creates compliance risk that disproportionately affects U.S. growers while imported hemp extracts face less stringent post-import testing.

The authors said foreign suppliers can ship CBD isolates and distillates that originated from high-THC hemp crops without facing the same pre-harvest testing burden, creating a competitive disadvantage for domestic farmers. The piece cited unnamed industry sources estimating that more than 40% of CBD ingredients in U.S. consumer products now originate from China and Eastern Europe, where enforcement of the 0.3% delta-9 THC limit occurs only at the point of U.S. Customs entry, not at cultivation.

The analysis highlighted that the 2018 Farm Bill's testing requirements apply to U.S. hemp farmers but do not mandate equivalent field-level compliance verification for foreign-grown hemp processed into extracts before importation. This regulatory asymmetry means domestic growers risk crop destruction if a single test exceeds 0.3% THC, while foreign processors can blend or remediate batches before export. The authors called for harmonized testing standards that apply identical pre-export testing requirements to imported hemp derivatives, arguing current rules undermine both domestic agriculture and consumer safety by obscuring the origin and testing history of CBD ingredients.

The piece noted that no federal agency currently tracks the country-of-origin for hemp extracts in finished goods, making it difficult for consumers or regulators to distinguish domestically grown CBD from imported material. The authors urged Congress to close this gap by requiring certificate-of-analysis documentation that traces CBD back to the farm level, regardless of where cultivation occurred.

Update — June 24, 2026: White House Urges Congress to Block November Hemp Recriminalization Deadline

The White House called on Congress to delay or repeal a November 2026 statutory deadline that would effectively recriminalize a broad category of intoxicating hemp products, according to a formal statement released by the Office of National Drug Control Policy. The deadline, embedded in prior appropriations language, requires the U.S. Department of Agriculture to withdraw federal protection for hemp-derived cannabinoids that produce intoxication unless Congress acts. The administration said the cutoff would create "unequal treatment" for hemp businesses operating under the 2018 Farm Bill framework.

White House officials said the administration supports "fair treatment of hemp products" and urged lawmakers to pass clarifying legislation before the November trigger date. The statement did not propose specific THC potency limits or age-gating requirements, but emphasized that any regulatory framework should align with existing state-level hemp programs. More than 30 states currently permit retail sales of delta-8 THC, delta-10 THC, and THC-O products derived from hemp, generating an estimated $2 billion in annual sales across convenience stores, vape shops, and online platforms.

Industry groups including the U.S. Hemp Roundtable and National Hemp Association praised the White House position, saying a sudden November ban would force immediate inventory destruction and expose retailers to federal enforcement risk. The Hemp Roundtable estimated that a recriminalization event would eliminate approximately 15,000 jobs in manufacturing, distribution, and retail sectors. Congressional aides said bipartisan discussions are underway in both the House and Senate Agriculture Committees, but no bill text has been introduced as of late June.

The November deadline originated in a 2024 appropriations rider that directed USDA to finalize rules distinguishing non-intoxicating hemp from controlled substances. When the agency missed the regulatory deadline, the rider's fallback provision automatically strips federal legal status from all hemp extracts with psychoactive effects. Failure to act by November would reclassify delta-8 THC and similar compounds as Schedule I controlled substances, subjecting manufacturers and retailers to potential Drug Enforcement Administration enforcement. The White House statement marks the first direct executive branch intervention in the intoxicating hemp debate since the 2018 Farm Bill legalized hemp cultivation.